Report from the Annual General Meeting in Bluefish Pharmaceuticals AB

The Annual General Meeting in Bluefish Pharmaceuticals AB was held on 22 April 2008 at 09.00 in Stockholm.

At the Annual General Meeting the following decisions were passed:

-The Meeting resolved to adopt the income statement and balance sheet inserted in the annual report for 2008 and to adopt the income statement and balance sheet inserted in the Group annual report for 2008.
-The Meeting resolved not to pay dividends to shareholders.
-The Meeting resolved to discharge the members of the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2008.
-The Meeting resolved to re-elect Erika Kjellberg Eriksson, Carl Palmstierna and Karl Karlsson as members of the Board of Directors until the end of the next Annual General Meeting.
- The Meeting resolved that the fees to the Board of Directors should amount to SEK 200,000 to the Chairman and SEK 100 000 each to the other Board members who are not employed by the company.
- The Meeting resolved to authorise the Board of Directors to resolve upon the issue of in total not more than 8,000,000 new A or B shares or the corresponding amount of warrants and convertible debentures with payment in kind, via settlement or other ways of subscription under conditions according to chapter 13 article 5 first paragraph 6 in the Swedish Companies Act.
-The Meeting resolved that fees to the company auditors will be paid at current account.

For more information, please contact: Karl Karlsson, CEO & President, tel +46 8 679 50 70